This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Hyperion Therapeutics Announces First Quarter 2014 Financial Results

Stocks in this article: HPTX

- Company signs definitive agreement to expand its pipeline - - Company to Host Conference Call Today at 4:30 p.m. ET (1:30 p.m. PT) -

BRISBANE, Calif., May 6, 2014 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today reported net revenue of $19.5 million for the first quarter of 2014 from the sales of its two products for the treatment of urea cycle disorders, RAVICTI ® (glycerol phenylbutyrate) Oral Liquid and BUPHENYL ® (sodium phenylbutyrate) Tablets and Powder. Adjusted net income for the first quarter 2014 was $3.8 million compared to an adjusted net loss of $8.5 million in the first quarter of 2013, an increase of $12.3 million. Hyperion ended the first quarter of 2014 with cash, cash equivalents and investments of $124.5 million.

"So far this year, we have strengthened our position in the orphan disease space by delivering on both commercial and corporate milestones. We achieved another quarter of solid revenue for our commercial products, and signed a definitive agreement to acquire Andromeda Biotech. DiaPep277, Andromeda's product candidate, is a highly differentiated, late-stage asset with the potential for near-term commercialization," said Donald J. Santel, president and chief executive officer of Hyperion. "With our two commercial products for urea cycle disorders, our pipeline program in hepatic encephalopathy, and the planned addition of DiaPep277, we believe we are well positioned to build both short and long-term value while advancing in our mission to develop and deliver life-changing treatments for patients suffering from orphan diseases."

First Quarter 2014 Financial Results

Net income as measured under U.S. generally accepted accounting principles ("GAAP") was $1.3 million, or $0.06 per diluted share, for the three months ended March 31, 2014 compared with a net loss of $9.0 million, or $(0.52) per diluted share, for the same period of 2013. Adjusted net income was $3.8 million, or $0.18 per diluted share, for the three months ended March 31, 2014 compared with an adjusted net loss of $8.5 million, or $(0.49) per diluted share, for the same period in 2013. A reconciliation of adjusted net income (loss) to GAAP net income (loss) is provided in the accompanying table below entitled "Reconciliation of GAAP Net Income (Loss) to Adjusted Net Income (Loss)."

1 of 6

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,085.67 +55.46 0.31%
S&P 500 2,089.96 +8.08 0.39%
NASDAQ 4,797.3820 +23.91 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs